There are no Transcripts on ICCC.
Thu, Sep. 18, 12:45 PM
Tue, Aug. 12, 10:11 AM
Tue, Aug. 12, 8:22 AM
Wed, Jul. 16, 11:30 AM
- Portland, ME-based ImmuCell (ICCC) details investors on the commercial opportunities of its key products.
- First Defense: oral antibodies derived fro bovine colostrum for the prevention of scours (bovine enteritis or diarrhea) in newborn calves. The annual economic losses to the U.S. dairy and beef industries due to scours is ~$761M. Its two main competitors are Zoetis' (ZTS +0.5%) Calf-Guard and Novartis' (NVS +0.2%) Bovine Ecolizer +C. All three products are used to treat ~3M calves per year or ~8% of the total calves born each year. First Defense's market share was ~25% in 2013 and is forecasted to grow to 28% this year.
- Mast Out: Nisin-based treatment for subclinical mastitis in lactating dairy cows (pending FDA approval). Mastitis costs the dairy industry ~$2B per year. The company states that the market potential for subclinical mastitis is difficult to assess because it is generally not treated due to the cost of discarding the milk (required). The company expects to revolutionize mastitis treatment by potentially eliminating the cost of discarding milk. It forecasts first year sales of ~$5.4M and ~$32M by the tenth year post launch at a SRP of $8.99 per dose.
Aug. 19, 2013, 12:45 PM| 2 Comments
Jul. 18, 2013, 3:19 PM
Jul. 18, 2013, 12:45 PM
There are no StockTalks on this stock yet.
ICCC vs. ETF Alternatives
Other News & PR